<unk>  (INN, trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes.<unk> , jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019.<unk>  is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor (gliflozin). These membrane proteins are on the cell surface and transfer glucose into the cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys.<unk>  reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2.
Ipragliflozin
Ertugliflozin
Liraglutide
Linagliptin
Exenatide
Saxagliptin
Vildagliptin
Sitagliptin